Phase II Trial of Dasatinib and Peginterferon Alpha-2b as First-Line Treatment for Chronic-Phase CML


Phase II Trial of Dasatinib and Peginterferon Alpha-2b as First-Line Treatment for Chronic-Phase CML
Slides from a presentation at ASH 2015

Roy L et al. Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: Preliminary results of a Phase II trial, from the French Intergroup of CML (Fi-LMC). Proc ASH 2015;Abstract 134.